Affimed N.V.
NASDAQ: AFMD0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Shawn Leland
- Employees
- 76
- Headquarters
- Mannheim, Germany
- IPO year
- 2014
- Market cap
- $3.0M
- Website
- https://www.affimed.com
Loading AFMD…
Loading profile data…Frequently asked questions about AFMD
What does Affimed N.V. (AFMD) do?
Affimed N.V. operates as a clinical-stage biopharmaceutical enterprise, concentrating its efforts on the identification and advancement of innovative cancer immunotherapies across the United States, Germany, and the broader European region. A key asset in their development pipeline is AFM13. This candidate has successfully concluded its Phase II...
Where does AFMD trade?
Affimed N.V. (AFMD) trades on the NASDAQ Global Market.
What sector is AFMD in?
Affimed N.V. (AFMD) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Affimed N.V.?
Shawn Leland is the chief executive officer of Affimed N.V. (AFMD).
Where is Affimed N.V. headquartered?
Affimed N.V. is headquartered in Germany.
Does AFMD pay a dividend?
Affimed N.V. (AFMD) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did AFMD go public?
Affimed N.V. (AFMD) completed its initial public offering in 2014.